Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spago Nanomedical ABFRA:7UX 32 Equity-to-Asset is 0.84 as of Jun. 2026, which is 13% below its 10-year median of 0.96. GuruFocus rates FRA:7UX with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 1,414 Biotechnology companies, Spago Nanomedical AB ranks better than 72.07% on this metric.
Spago Nanomedical AB (FRA:7UX) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Spago Nanomedical AB Equity-to-Asset Related Terms
Spago Nanomedical AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Spago Nanomedical AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7UX vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Spago Nanomedical AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spago Nanomedical AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Spago Nanomedical AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Spago Nanomedical AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spago Nanomedical AB (FRA:7UX) has a Equity-to-Asset of 0.84 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Spago Nanomedical AB and its competitors. This is 13% below median its historical median of 0.96. Over the past decade, Spago Nanomedical AB's Equity-to-Asset has ranged from 0.72 to 0.98. According to the industry distribution chart, Spago Nanomedical AB ranks #395 out of 1414 companies in the Biotechnology industry, placing it in the top 27.9%.
Is Spago Nanomedical AB's Equity-to-Asset too high?
Spago Nanomedical AB's current Equity-to-Asset of 0.84 is 13% below median its 10-year median of 0.96. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 0.98. The Biotechnology industry median Equity-to-Asset is 0.68. Spago Nanomedical AB's value of 0.84 is 23.5% above this industry median. Based on the distribution chart, Spago Nanomedical AB ranks #395 out of 1414 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Spago Nanomedical AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Spago Nanomedical AB ranks #395 out of 1414 companies for Equity-to-Asset. This puts Spago Nanomedical AB in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Spago Nanomedical AB's value of 0.84 is 23.5% above this benchmark. Historically, Spago Nanomedical AB's own Equity-to-Asset has ranged from 0.72 to 0.98 over the past decade. While the company's 10-year median is 0.96 vs. the industry median of 0.68, Spago Nanomedical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spago Nanomedical AB's current Equity-to-Asset of 0.84 is 23.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Spago Nanomedical AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spago Nanomedical AB's current Equity-to-Asset is 0.84, which is 13% below median its own 10-year median of 0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Spago Nanomedical AB (FRA:7UX) has a current Equity-to-Asset of 0.84. The current Equity-to-Asset is 0.84, which is 13% below median its 10-year median of 0.96 and 23.5% above the Biotechnology industry median of 0.68. Spago Nanomedical AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Spago Nanomedical AB (FRA:7UX), the current Equity-to-Asset is 0.84 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
32GF Score
Get the complete analysis for FRA:7UX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7UX has been successfully added to your 
